Integrated 5-HT<sub>2A</sub>-TrkB and G protein signaling in serotonergic psychedelic responses. [PDF]
Taddei-Tardón M +8 more
europepmc +1 more source
The working lives of neuronal 5-HT<sub>2A</sub> receptors from the outside in. [PDF]
Jabar A, Pinto M, Hébert TE.
europepmc +1 more source
Long-Term Benefits of Chronic 5-HT2A Antagonist and 5-HT1A Agonist Treatment on ADHD Behavior in Juvenile Spontaneously Hypertensive Rats. [PDF]
Madhyastha S, Rao MS.
europepmc +1 more source
Novel Phenethylamines as 5‑HT2A Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD, and Neuropathic Pain. [PDF]
Sabnis RW.
europepmc +1 more source
The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents. [PDF]
Nadal-Gratacós N +22 more
europepmc +1 more source
Novel Fused Heterocycles as 5‑HT2A Receptor Agonists for Treating Neurological Diseases, Namely, Depression, Anxiety, Substance Abuse, and Headaches. [PDF]
Sabnis RW.
europepmc +1 more source
Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders. [PDF]
Sabnis RW, Sabnis AR.
europepmc +1 more source
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses. [PDF]
Sabnis RW, Sabnis AR.
europepmc +1 more source
A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox. [PDF]
Pei G.
europepmc +1 more source
5-HT <sub>2A</sub> receptor in medial prefrontal cortex mediates pain-related empathic responses in rats. [PDF]
Luo WJ +6 more
europepmc +1 more source

